Share This Page
Drugs in ATC Class G03XB
✉ Email this page to a colleague
Drugs in ATC Class: G03XB - Progesterone receptor modulators
| Tradename | Generic Name |
|---|---|
| KORLYM | mifepristone |
| MIFEPREX | mifepristone |
| MIFEPRISTONE | mifepristone |
| ELLA | ulipristal acetate |
| LOGILIA | ulipristal acetate |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class G03XB: Progesterone Receptor Modulators
Progesterone receptor modulators in ATC class G03XB span oral and injectable progestin drugs and progesterone receptor antagonists used in gynecology and reproductive medicine. Patent and market exclusivity outcomes are dominated by (1) long-running composition and method-of-use filings around specific active ingredients, (2) formulation IP for oral solids and injectable depots, and (3) regulatory exclusivity layers that can delay generic entry even after primary patents expire. Competitive dynamics increasingly hinge on whether follow-on patents cover patient selection and dose regimens, and whether ANDA filers can design around those claims.
Which progesterone receptor modulators are in ATC Class G03XB, and how do they drive market dynamics?
ATC G03XB is the progesterone receptor modulator class. Commercial exposure is concentrated in a small set of active ingredients that correspond to branded specialty reproductive and gynecology products. Market dynamics depend on:
- Indication mix (endometriosis, uterine fibroids, infertility support, abnormal uterine bleeding, dysmenorrhea, menopause-related bleeding pathways where progesterone modulation is used)
- Route and formulation (oral immediate release vs extended release; injectables and long-acting depots)
- Site-of-care and reimbursement (outpatient specialty pharmacy vs clinic-administered injection)
- Competitive timing (primary patent cliffs vs follow-on patent density)
What sub-therapeutic areas shape demand for G03XB drugs?
Common demand drivers include:
- Chronic gynecologic conditions treated with sustained dosing
- Short-course reproductive protocols where dosing schedules can affect method-of-use patent scope
- Provider preference and product switching friction for injectable depots
How do route and formulation affect patent barriers?
Oral molecules tend to attract:
- Salt/crystal form claims
- Manufacturing/process claims
- Bioavailability and dissolution-related formulation claims
Injectables and depots tend to attract:
- Sterile manufacturing and particle size or viscosity ranges
- Sustained-release matrix claims
- Injection system and depot performance parameters
What patents protect progesterone receptor modulators in ATC Class G03XB?
Featured snippet answer: Protection typically falls into three layers: active ingredient composition, formulation/manufacturing refinements, and method-of-use claims tied to specific indications, dosing regimens, and patient populations.
How is patent scope usually structured across G03XB?
A typical G03XB patent estate includes:
-
Composition of matter
- Chemical entities (active ingredients)
- Salts, solvates, polymorphs, hydrates
- Intermediate and process chemistry that supports the final compound
-
Pharmaceutical compositions and formulations
- Dosage forms (tablets, capsules, sustained-release pellets)
- Excipients and controlled-release matrices
- Particle engineering, dissolution control, and bioavailability targets
-
Method-of-use and treatment regimens
- Indication claims (specific gynecologic diagnoses)
- Dosing schedules (initiation dose, taper, maintenance intervals)
- Patient selection variables (prior therapy response, disease stage markers)
-
Manufacturing methods
- Sterile fill-finish and aseptic processing for injectables
- Heat-treatment, solvent systems, and crystallization controls
- Scale-up process parameters
Where do design-around strategies usually succeed?
- If formulation patents are narrow to specific excipient systems and release profiles, ANDA filers may pursue alternative release mechanisms.
- If method-of-use patents claim specific regimens, label carve-outs can reduce generic entry risk only if the carve-out is credible and enforceable.
- If manufacturing patents are broad but tied to a specific process, licensors often show generic manufacturing differences that can preserve noninfringement.
When do progesterone receptor modulator patents expire in ATC Class G03XB?
Featured snippet answer: Exclusivity timing is typically driven by earliest priority dates of the active ingredient, then extended by follow-on formulation and method-of-use patents that expire later. Regulatory exclusivity can delay generic approval even when patents lapse.
What are the typical exclusivity timelines that affect entry?
Across branded G03XB products, generic entry timing is usually a function of:
- Primary composition patents (often the earliest expiration anchor)
- Secondary patents (formulation, polymorph, depot performance, and dosing regimen)
- Regulatory exclusivity
- 5-year New Chemical Entity exclusivity where applicable
- 3-year New Clinical Investigation exclusivity
- Orphan Drug exclusivity where a product qualifies
- 7-year Biological exclusivity if any G03XB products are biologics (most are small molecules, but not universally)
How do follow-on patents change “expiration” outcomes?
A “patent cliff” often does not translate into generic entry because:
- The branded company can still assert a later-expiring formulation or regimen patent
- Settlement agreements can extend the effective exclusion date beyond the earliest theoretical expiration
What Orange Book status should you expect for G03XB progesterone receptor modulators?
Featured snippet answer: Most G03XB progesterone receptor modulators appear in the FDA Orange Book under the listed drug (RLD), with at least one patent tied to the active ingredient and one or more patents tied to formulation and use.
What Orange Book patent types drive generic filing risk?
- Drug Substance patents (composition and active ingredient)
- Drug Product patents (formulation and dosage form)
- Method-of-Use patents (indication and dosing regimen)
How do Orange Book listings impact Paragraph IV incentives?
- High-density patent listings with method-of-use coverage increase the odds that generic challengers face multiple asserted patents in litigation.
- Where Orange Book listings include regimen-specific patents, ANDA filers may need to pursue label limitations or design around to reduce infringement risk.
How strong is the patent estate for progesterone receptor modulators in G03XB?
Featured snippet answer: Patent strength is usually highest when method-of-use and formulation patents are both broad and supported by strong experimental data showing improved performance in the claimed regimen or release profile.
Patent strength indicators used in enforcement
- Breadth of claims across dosage regimens and patient subgroups
- Correlation between claims and the commercial label
- Number of separately asserted patents per active ingredient
- Whether follow-on patents are continuation-heavy or rely on earlier disclosure
- Litigation history: prior claim construction outcomes, settlement patterns, and injunction outcomes
What litigation patterns are common in G03XB?
Typical patterns across progesterone-receptor-focused products:
- Multiple Paragraph IV filings against the same RLD
- Settlement agreements that delay launch while preserving the brand’s market share
- Focused disputes on dosing regimen infringement and formulation release characteristics
What generic entry risks exist for ATC G03XB progesterone receptor modulators?
Featured snippet answer: Generic entry risk concentrates on label design around method-of-use patents and formulation design around controlled-release or depot performance patents. If a generic can’t credibly change the labeled regimen or release mechanism, it faces higher litigation and launch delay risk.
What are the most common generic filing scenarios?
-
Full label ANDA
- High infringement risk if method-of-use patents exist for the labeled indication
- Higher likelihood of injunction or delayed launch via settlement
-
Carve-out label ANDA
- Lower risk only if the carve-out avoids all asserted method-of-use claims
- High execution burden: the generic label must be consistent with the ANDA submission and enforceable
-
Formulation design-around
- Different excipient system or release kinetics
- Works best when drug product patents are narrow and tethered to specific formulation parameters
How do settlements affect launch timing?
- Settlements often produce “shared market” arrangements or date-certain entry triggers.
- The key business variable is the earliest date for which a generic can launch without violating settlement and without infringing remaining patents.
Which companies are challenging G03XB progesterone receptor modulators with Paragraph IV ANDAs?
A defensible, data-backed list requires an Orange Book patent-by-patent review tied to each G03XB RLD and each ANDA filing. Without identified RLDs, patent numbers, and FDA filing identifiers, an accurate company-by-company challenge map cannot be produced.
What patent litigation affects progesterone receptor modulators in G03XB?
A defensible litigation impact analysis requires case identifiers, asserted patent numbers, and jurisdictional outcomes tied to specific products in G03XB. Without those product-level inputs, a complete and accurate litigation landscape cannot be produced.
How do progesterone receptor modulators compare with each other in patent and market risk?
Even within the same ATC class, relative risk varies by:
- Whether the drug is long-established vs recently introduced
- Whether it has a dense formulation-follow-on strategy
- Whether it has method-of-use claims matching widely used dosing regimens
What to compare when building a competitive risk model
- Patent estate size (count of Orange Book entries by patent type)
- Remaining “endgame” patents at predicted generic filing dates
- Likelihood that method-of-use claims match real-world prescribing patterns
- Whether formulations require specialized manufacturing controls that create higher ANDA development friction
Do biologic exclusivities matter for ATC Class G03XB progesterone receptor modulators?
Featured snippet answer: Most G03XB progesterone receptor modulators are small-molecule drugs, so biologic exclusivity frameworks are usually not the primary driver. The relevant exclusivity typically comes from NDA-era small molecule exclusivity and patent listings in the Orange Book.
What manufacturing and IP barriers slow generic entry for G03XB drugs?
Featured snippet answer: For oral solids, dissolution and bioavailability controls drive product patent risk. For injectables and depot systems, sterile manufacturing and sustained-release performance requirements drive product development time and patent exposure.
Manufacturing bottlenecks that elevate timelines
- Tight specifications for particle size and distribution (oral)
- Moisture and polymorph control during scale-up
- Aseptic processing and container closure system constraints (injectables)
- Reproducible sustained-release matrix behavior (depots)
IP-linked development workstreams
- Formulation scientists reverse-engineer release profiles and bioavailability
- Regulatory teams align CMC packages with design-around strategies
- Litigation teams map patent claim elements to manufacturing and analytical testing results
How do licensing deals and settlements influence market share in G03XB?
Featured snippet answer: In progesterone receptor modulator categories, licensing and settlements most often determine who gets to launch next and on what label scope. Where brand companies maintain a strong endgame around method-of-use and formulation patents, settlements are typically structured around delayed launch dates or partial carve-outs.
Settlement economics that matter
- Date-certain launch triggers
- Royalty terms or shared profits arrangements
- Non-expiry: continued enforcement of remaining patents even post-launch by delaying workarounds
Key Takeaways
- G03XB progesterone receptor modulators typically face layered exclusivity: active ingredient composition plus formulation and method-of-use follow-ons.
- Orange Book patent density, especially method-of-use listings, is the primary driver of generic entry risk.
- Market timing is usually determined less by earliest patent expiration and more by later-expiring drug product and regimen patents plus settlement-driven launch delays.
- Practical barriers for ANDA filers center on proving noninfringement through formulation release design and label regimen carve-outs.
FAQs
Which delivery systems for progesterone receptor modulators have the highest formulation patent risk?
Sustained-release oral formulations and depot injectables usually carry the highest drug product and performance-parameter patent risk due to tighter linkage between CMC attributes and claim elements.
How do method-of-use patents affect label carve-out strategy for generic applicants?
Method-of-use claims can force generics into indication and dosing limitations; a carve-out must avoid every claimed regimen element that maps to the proposed label.
What Orange Book patent types tend to be most litigated in progesterone receptor modulator cases?
Method-of-use and drug product patents are commonly litigated because they align closely with marketed dosing regimens and observable product characteristics.
Do polymorph or salt patents commonly create long-lived exclusivity for G03XB drugs?
Yes, where follow-on patents cover specific crystalline forms or salt states that underpin manufacturing reproducibility and bioavailability.
What is the typical business impact of settlement agreements on generic entry dates?
Settlements frequently produce date-certain launch delays and label limitations that preserve brand market share until the settlement trigger.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
More… ↓
